Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service, Merger/Acquisition

Kronos Bio and Gilead Sciences Enter Into Asset Purchase Agreement for Gilead's SYK Inhibitor Portfolio


Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that it has entered into an asset purchase agreement with Gilead Sciences, Inc. to acquire Gilead's spleen tyrosine kinase (SYK) inhibitor portfolio. The portfolio includes the clinical stage compounds entospletinib, which has been evaluated in Phase 1 and Phase 2 clinical trials in oncology patients, and lanraplenib, which has been evaluated in Phase 2 clinical trials in patients with autoimmune diseases.

"Kronos is uniquely positioned to advance these differentiated and selective SYK inhibitors by leveraging our expertise in oncology and transcriptional regulatory networks," said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. "We believe the acquisition of these compounds not only propels us more quickly into clinical development but also brings us closer to our goal of transforming patient outcomes."

Kronos intends to initially focus on developing the SYK inhibitor program in a biomarker-defined subset of patients with acute myelogenous leukemia (AML). SYK is a critical node in AML overexpressing the HOXA9 and MEIS1 transcription factors. HOXA9 and MEIS1 become dysregulated as a result of recurring mutations found in up to one half of AML patients.

"Despite recent advancements in AML, there remains a substantial need for targeted therapies that can extend life," said John Byrd, M.D., D. Warren Brown Chair of Leukemia Research, and Distinguished University Professor of The Ohio State University Comprehensive Cancer Center and Chief Medical Officer of The Leukemia & Lymphoma Society Beat AML Trial. "SYK inhibition has demonstrated promising activity in clinical trials of AML patients who have high HOXA9/MEIS1 expression and is an optimal target for further clinical research to understand how HOXA9/MEIS1 dysregulation drives AML in these patients. The Beat AML Trial directed by The Leukemia & Lymphoma Society has partnered closely with Gilead and looks forward to continued close collaboration with Kronos Bio."

Entospletinib has produced promising early clinical data in a biomarker-defined subset of AML patients (Liu, et al. EHA poster abstract PF246, 2018). Entospletinib has been investigated in over 500 patients across six Gilead sponsored studies in a variety of hematologic malignancies, including AML, demonstrating activity as a single-agent and in combination with standard-of-care.

Lanraplenib has been investigated in over 250 patients across seven Gilead sponsored studies in various autoimmune diseases. Its pharmaceutical properties may make it a commercially attractive next generation product candidate.

Under the terms of the agreement, Gilead will receive an upfront cash payment and a note convertible into Kronos equity, and will be eligible to receive regulatory and commercial milestones and royalties on future sales of products arising from the acquired programs.

About Kronos Bio

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.


These press releases may also interest you

at 13:05
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor...

at 13:00
The Government of Canada is committed to building a clean energy future to strengthen the economy, create good jobs and support our natural resource sectors. This commitment will be more important than ever as we reopen the economy and plan our...

at 12:45
Professor Wilhelm J. Ansorge, after a long scientific career at top laboratories (Texas Instruments, CERN, and EMBL), is now a visiting scientist in several European Institutes, serving on Scientific Advisory Boards, and evaluating scientific...

at 12:30
The "Bioprocessing System Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Product Type" report has been added to ResearchAndMarkets.com's offering. This report describes the global market size of...

at 12:30
The "North America Revenue Assurance Market By Component, By Deployment Type, By Vertical, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The North America Revenue Assurance...

at 12:15
The "DevOps - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Forced to Redefine Productivity in the Age of COVID-19, DevOps Gets an Unexpected 29.4% Boost in Demand The global market for DevOps is...



News published on 16 july 2020 at 08:35 and distributed by: